Document:

EX-10.10

 EXHIBIT 10.10 

INDEMNIFICATION AGREEMENT 

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this      day of
            , 2014, by and between Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and
                                        
(“Indemnitee”). 
 WHEREAS, qualified persons are reluctant to serve corporations as directors, officers or otherwise unless they
are provided with broad indemnification and insurance against claims arising out of their service to and activities on behalf of such corporations; and 

WHEREAS, the Company has determined that attracting and retaining such persons is in the best interests of the Company’s stockholders and
that it is reasonable, prudent and necessary for the Company to indemnify such persons to the fullest extent permitted by applicable law and to provide reasonable assurance regarding insurance; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and Indemnitee,
each intending to be legally bound, hereby agree as follows: 
  

	 	1.	Defined Terms; Construction. 

 (a) Defined Terms. As used in this Agreement, the
following terms shall have the following meanings: 
 “Board of Directors” means the Board of Directors of the Company. 

“Change in Control” means, and shall be deemed to have occurred if, on or after the date of this Agreement, (i) any
“person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act, as amended), other than (A) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its
subsidiaries acting in such capacity, or (B) a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company, is or becomes the
“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than twenty percent (20%) of the total voting power represented by the Company’s then
outstanding Voting Securities, (ii) during any period of two (2) consecutive years, individuals who at the beginning of any such period constitute the Board of Directors and any new director whose election by the Board of Directors
or nomination for election by the Company’s stockholders was approved by a resolution of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or
nomination for election was previously so approved, cease for any reason to constitute a majority thereof, (iii) the stockholders of the Company approve a merger or consolidation of the Company with any other entity other than a merger
or consolidation that would result in the Voting Securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving entity) at least
eighty percent (80%) of the total voting power represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, (iv) the stockholders of the Company approve a
plan of complete liquidation of the Company or an agreement for the sale or disposition by the 

 
Company (in one (1) transaction or a series of related transactions) of all or substantially all of its assets, or (v) the Company shall file or have filed against it, and such
filing shall not be dismissed, any bankruptcy, insolvency or dissolution proceedings, or a trustee, administrator or creditors committee shall be appointed to manage or supervise the affairs of the Company. 

“Corporate Status” means the status of a person who is, becomes, was or may be deemed to be a director (or a member of any committee
of the Board of Directors), officer, employee or agent (including without limitation a manager of a limited liability company or general partner of a limited partnership) of the Company or any of its subsidiaries, or of any predecessor thereof, or
is, begins or was serving at the request of the Company as a director (or a member of any committee of the Board of Directors), officer, employee or agent (including without limitation a manager of a limited liability company) of another entity, or
of any predecessor thereof, including service with respect to an employee benefit plan. 
 “Determination” means a determination
that either (x) there is a reasonable basis for the conclusion that indemnification of Indemnitee is proper in the circumstances because Indemnitee met a particular standard of conduct (a “Favorable Determination”) or
(y) there is no reasonable basis for the conclusion that indemnification of Indemnitee is proper in the circumstances because Indemnitee met a particular standard of conduct (an “Adverse Determination”). An Adverse
Determination shall include the decision that a Determination was required in connection with indemnification and the decision as to the applicable standard of conduct. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Expenses” means all (i) attorneys’ fees and expenses, retainers, court, arbitration and mediation costs, transcription
costs, fees and expenses of experts, witness and public relations consultants bonds and fees, traveling expenses, costs of collecting and producing documents, duplication costs, printing and binding costs, telephone charges, postage, delivery
service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, appealing or otherwise
participating in a Proceeding or responding to, or objecting to, a request to provide discovery in any Proceeding, (ii) damages, judgments, fines and amounts paid in settlement and any other amounts that Indemnitee becomes legally obligated to
pay (including any federal, state or local taxes and ERISA excise taxes imposed on Indemnitee as a result of receipt of reimbursements or advances of expenses under this Agreement) and (iii) the premium, security for, and other costs relating
to any costs bond, supersedes bond or other appeal bond or its equivalent, whether civil, criminal, arbitrational, administrative or investigative with respect to any Proceeding actually and reasonably incurred by Indemnitee, or on Indemnitee’s
behalf, because of any claim or claims made against or by him in connection with any Proceeding, whether formal or informal (including an action by or in the right of the Company), to which Indemnitee is, was or at any time becomes a party or a
witness, or is threatened to be made a party to, participant in or a witness with respect to, by reason of Indemnitee’s Corporate Status. 

“Independent Legal Counsel” means an attorney or firm of attorneys competent to render an opinion under the applicable law, selected
in accordance with the provisions of Section 5(e), who has not performed any services (other than services similar to those contemplated to be performed by Independent Legal Counsel under this Agreement) for the Company or any of its
subsidiaries or for Indemnitee within the last three years. 

  
 2 

 “NRS” means the Nevada Revised Statutes, as amended from time to time. 

“Proceeding” means a threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
investigative, including without limitation a claim, demand, discovery request, formal or informal investigation, inquiry, administrative hearing, arbitration or other form of alternative dispute resolution, including an appeal from any of the
foregoing. 
 “Voting Securities” means any securities of the Company that vote generally in the election of directors. 

(b) Construction. For purposes of this Agreement, 

(i) References to the Company and any of its “subsidiaries” shall include any corporation, limited liability company,
partnership, joint venture, trust or other entity or enterprise that before or after the date of this Agreement is party to a merger or consolidation with the Company or any such subsidiary or that is a successor to the Company as contemplated by
Section 8(e) (whether or not such successor has executed and delivered the written agreement contemplated by Section 8(e)). 

(ii) References to “fines” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit
plan. 
 (iii) References to a “witness” in connection with a Proceeding shall include any interviewee or person
called upon to produce documents in connection with such Proceeding. 
  

	 	2.	Agreement to Serve. 

 Indemnitee agrees to serve as a director of the Company, an officer
of the Company, or both, and/or to serve as a director, officer or both of one or more of the Company’s subsidiaries and in such other capacities as Indemnitee may serve at the request of the Company from time to time, and by its execution of
this Agreement the Company confirms its request that Indemnitee serve as a director, officer and in such other capacities. Indemnitee shall be entitled to resign or otherwise terminate such service with immediate effect at any time, and neither such
resignation, termination nor the length of such service shall affect Indemnitee’s rights under this Agreement. This Agreement shall not constitute an employment agreement, supersede any employment agreement to which Indemnitee is a party or
create any right of Indemnitee to continued employment or appointment. 
  

	 	3.	Indemnification. 

 (a) General Indemnification. The Company shall indemnify
Indemnitee, to the fullest extent permitted by applicable law in effect on the date hereof or as amended to increase the scope of permitted indemnification, against Expenses, losses, liabilities, judgments,

  
 3 

 
fines, penalties and amounts paid in settlement (including all interest, taxes, assessments and other charges in connection therewith) incurred by Indemnitee or on Indemnitee’s behalf in
connection with any Proceeding connected with, resulting from or relating to Indemnitee’s Corporate Status. 
 (b) Additional
Indemnification Regarding Expenses. Without limiting the foregoing, in the event any Proceeding is initiated by Indemnitee, the Company or any other person (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) to enforce or
interpret this Agreement or any rights of Indemnitee to indemnification or advancement of Expenses (or related obligations of Indemnitee) under the Company’s or any such subsidiary’s articles or certificate of incorporation, bylaws or
other organizational agreement or instrument of the Company, any other agreement to which Indemnitee and the Company or any of its subsidiaries are party, any vote of the stockholders or resolution of the directors of the Company or any of its
subsidiaries, the NRS, any other applicable law or any liability insurance policy, the Company shall indemnify Indemnitee against Expenses incurred by Indemnitee or on Indemnitee’s behalf in connection with such Proceeding in proportion to the
success achieved by Indemnitee in such Proceeding and the efforts required to obtain such success, as determined by the court presiding over such Proceeding. 

(c) Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for a
portion of any Expenses, losses, liabilities, judgments, fines, penalties and amounts paid in settlement incurred by Indemnitee, but not for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for such portion. 

(d) Nonexclusivity. The indemnification provided by this Agreement shall not be deemed exclusive of any rights to which Indemnitee may
be entitled under the certificate of incorporation, bylaws or other organizational agreement or instrument of the Company or any of its subsidiaries, any other agreement, any vote of the stockholders or resolution of the directors, the NRS, any
other applicable law or any liability insurance policy. 
 (e) Exceptions. Any other provision herein to the contrary
notwithstanding, the Company shall not be obligated under the Agreement to indemnify Indemnitee: 
 (i) For Expenses incurred
in connection with Proceedings initiated or brought voluntarily by Indemnitee and not by way of defense, counterclaim or crossclaim, except (x) as contemplated by Section 3(b), (y) in specific cases if the Board
of Directors has approved the initiation or bringing of such Proceeding, and (z) as may be required by law. 

(ii) For an accounting of profits arising from the purchase and sale by Indemnitee of securities within the meaning of
Section 16(b) of the Exchange Act, or any similar provisions of any federal, state or local law if the final, non-appealable judgment of a court of competent jurisdiction finds Indemnitee to be liable for disgorgement under such
Section 16(b). 

  
 4 

 (iii) On account of Indemnitee’s acts or omissions that are established by a
final adjudication as involving intentional misconduct, fraud or a knowing violation of the law and, in each case, that was material to the cause of action. 

(iv) For which payment is actually made to Indemnitee under a valid and collectible insurance policy or under a valid and
enforceable indemnity clause, bylaw or agreement, except in respect of any excess beyond payment actually received by Indemnitee under such insurance, clause, bylaw or agreement. 

(v) if and to the extent indemnification is prohibited by applicable law. 

(f) Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of
the rights of recovery of Indemnitee, who shall execute such documents and do such acts as the Company may reasonably request to secure such rights and to enable the Company effectively to bring suit to enforce such rights. 

 

	 	4.	Advancement of Expenses. 

 To the fullest extent permitted by law, the Company shall pay
all Expenses incurred by Indemnitee in connection with any Proceeding connected with, resulting from or relating to Indemnitee’s Corporate Status, other than a Proceeding initiated by Indemnitee for which the Company would not be obligated to
indemnify Indemnitee pursuant to Section 3(e)(i), in advance of the final disposition (in accordance with Section 5(c)) of such Proceeding and without regard to whether Indemnitee will ultimately be entitled to be indemnified
for such Expenses and without regard to whether an Adverse Determination has been made, except as contemplated by the last sentence of Section 5(f). The right to advances under this Section 4 shall in all instances continue
until final disposition of any Proceeding, including any appeal therein. Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under
the other provisions of this Agreement. Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, and Indemnitee shall repay such amounts advanced only if and to the extent that it shall ultimately be
determined in a decision by a court of competent jurisdiction from which no appeal can be taken that Indemnitee is not entitled to be indemnified by the Company for such Expenses. The right to advancement described in this Section 4 is
vested. Any repayment obligation shall be unsecured and shall not bear interest. The Company shall not impose on Indemnitee any additional conditions to advancement or require from Indemnitee additional undertakings regarding repayment. 

 

	 	5.	Indemnification Procedure. 

 (a) Notice of Proceeding; Cooperation. Indemnitee
shall give the Company notice in writing as soon as practicable, and in any event, no later than thirty (30) days after Indemnitee becomes aware, of any Proceeding for which indemnification will or could be sought under this Agreement,
provided that any failure or delay in giving such notice shall not relieve the Company of its obligations under this Agreement unless and to the extent that (i) none of the Company and its subsidiaries are party to or aware of such
Proceeding and (ii) the Company is materially prejudiced by such failure or delay. 

  
 5 

 (b) Settlement. The Company will not, without the prior written consent of Indemnitee,
which may be provided or withheld in Indemnitee’s sole discretion, effect any settlement of any Proceeding against Indemnitee or which could have been brought against Indemnitee unless such settlement solely involves the payment of money by
persons other than Indemnitee and includes an unconditional release of Indemnitee from all liability on any matters that are the subject of such Proceeding and an acknowledgment that Indemnitee denies all wrongdoing in connection with such matters.
The Company shall not be obligated to indemnify Indemnitee against amounts paid in settlement of a Proceeding against Indemnitee if such settlement is effected by Indemnitee without the Company’s prior written consent, which shall not be
unreasonably withheld. 
 (c) Request for Payment; Timing of Payment. To obtain indemnification payments or advances under this
Agreement, Indemnitee shall submit to a Company a written request therefor, together with such invoices or other supporting information as may be reasonably requested by the Company and reasonably available to Indemnitee. The Company shall make
indemnification payments to Indemnitee no later than sixty (60) days, and advances to Indemnitee no later than twenty (20) days, after receipt of such written request from Indemnitee. 

(d) Determination. The Company intends that Indemnitee shall be indemnified to the fullest extent permitted by applicable law as
provided in Section 3 and that no Determination shall be required in connection with such indemnification. In no event shall a Determination be required in connection with the advancement of Expenses pursuant to Section 4 or
in connection with the indemnification for Expenses incurred as a witness or incurred in connection with any Proceeding or portion thereof with respect to which Indemnitee has been successful on the merits or otherwise. Any decision that a
Determination is required by law in connection with any other indemnification of Indemnitee, and any such Determination, shall be made within thirty (30) days after receipt of Indemnitee’s written request for indemnification, as follows:

 (i) If no Change in Control has occurred, (w) by a resolution of a majority of the directors of the Company
who are not parties to such Proceeding, even if less than a quorum, with the advice of Independent Legal Counsel, or (x) by a committee of such directors designated by a resolution of a majority of such directors, even if less than a
quorum, with the advice of Independent Legal Counsel, or (y) if there are no such directors, or if such directors so direct, by Independent Legal Counsel in a written opinion to the Company and Indemnitee, or (z) by the vote
of holders of shares of capital stock of the Company then outstanding that vote generally in the election of directors. 

(ii) If a Change in Control has occurred, by Independent Legal Counsel in a written opinion to the Company and Indemnitee. 

The Company shall pay all Expenses incurred by Indemnitee in connection with a Determination. 

(e) Independent Legal Counsel. If there has not been a Change in Control, Independent Legal Counsel shall be selected by the Board of
Directors and approved by 

  
 6 

 
Indemnitee (which approval shall not be unreasonably withheld or delayed). If there has been a Change in Control, Independent Legal Counsel shall be selected by Indemnitee and approved by the
Company (which approval shall not be unreasonably withheld or delayed). The Company shall pay the fees and expenses of Independent Legal Counsel and indemnify Independent Legal Counsel against any and all expenses (including attorneys’ fees),
claims, liabilities and damages arising out of or relating to its engagement. 
 (f) Consequences of Determination; Remedies of
Indemnitee. The Company shall be bound by and shall have no right to challenge a Favorable Determination. If an Adverse Determination is made, or if for any other reason the Company does not make timely indemnification payments or advances of
Expenses, Indemnitee shall have the right to commence a Proceeding before a court of competent jurisdiction to challenge such Adverse Determination and/or to require the Company to make such payments or advances. Indemnitee shall be entitled to be
indemnified for all Expenses incurred in connection with such a Proceeding in accordance with Section 3(b) and to have such Expenses advanced by the Company in accordance with Section 4. If Indemnitee fails to timely
challenge an Adverse Determination, or if Indemnitee challenges an Adverse Determination and such Adverse Determination has been upheld by a final judgment of a court of competent jurisdiction from which no appeal can be taken, then, to the extent
and only to the extent required by such Adverse Determination or final judgment, the Company shall not be obligated to indemnify or advance Expenses to Indemnitee under this Agreement. 

(g) Presumptions; Burden and Standard of Proof. In connection with any Determination, or any review of any Determination, by any
person, including a court: 
 (i) It shall be a presumption that a Determination is not required. 

(ii) It shall be a presumption that Indemnitee has met the applicable standard of conduct and that indemnification of
Indemnitee is proper in the circumstances. 
 (iii) The burden of proof shall be on the Company to overcome the presumptions
set forth in the preceding clauses (i) and (ii), and each such presumption shall only be overcome if the Company establishes that there is no reasonable basis to support it. 

(iv) The termination of any Proceeding by judgment, order, finding, settlement (whether with or without court approval) or
conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that indemnification is not proper or that Indemnitee did not meet the applicable standard of conduct or that a court has determined that
indemnification is not permitted by this Agreement or otherwise. 
 (v) Neither the failure of any person or persons to have
made a Determination nor an Adverse Determination by any person or persons shall be a defense to Indemnitee’s claim or create a presumption that Indemnitee did not meet the applicable standard of conduct, and any Proceeding commenced by
Indemnitee pursuant to Section 5(f) shall be de novo with respect to all determinations of fact and law. 

  
 7 

	 	6.	Directors and Officers Liability Insurance. 

 (a) Maintenance of Insurance. So
long as the Company or any of its subsidiaries maintains liability insurance for any directors, officers, employees or agents of any such person, the Company shall ensure that Indemnitee is covered by such insurance in such a manner as to provide
Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s and its subsidiaries’ then current directors and officers. If at any date (i) such insurance ceases to cover acts and omissions
occurring during all or any part of the period of Indemnitee’s Corporate Status or (ii) neither the Company nor any of its subsidiaries maintains any such insurance, the Company shall ensure that Indemnitee is covered, with respect to acts
and omissions prior to such date, for at least six years (or such shorter period as is available on commercially reasonable terms) from such date, by other directors and officers liability insurance, in amounts and on terms (including the portion of
the period of Indemnitee’s Corporate Status covered) no less favorable to Indemnitee than the amounts and terms of the liability insurance maintained by the Company on the date hereof. 

(b) Notice to Insurers. Upon receipt of written notice of a Proceeding pursuant to Section 5(a), the Company shall give or
cause to be given prompt notice of such Proceeding to all insurers providing liability insurance in accordance with the procedures set forth in all applicable or potentially applicable policies. The Company shall thereafter take all necessary action
to cause such insurers to pay all amounts payable in accordance with the terms of such policies. 
  

	 	7.	Exculpation, etc. 

 (a) Limitation of Liability. The liability of directors and
officers of the Company shall be eliminated or limited to the fullest extent permitted by the NRS. If the NRS or such other applicable law shall be amended to permit further elimination or limitation of or authorize corporate action further
eliminating or limiting the personal liability of directors and/or officers, then the liability of Indemnitee shall, automatically, without any further action, be eliminated or limited to the fullest extent permitted by the NRS or such other
applicable law as so amended. 
 (b) Period of Limitations. No legal action shall be brought and no cause of action shall be asserted
by or in the right of the Company or any of its subsidiaries against Indemnitee or Indemnitee’s estate, spouses, heirs, executors, personal or legal representatives, administrators or assigns after the expiration of two (2) years from the
date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two (2) year period, provided, however,
that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter period shall govern. 
  

	 	8.	Miscellaneous. 

 (a) Non-Circumvention. The Company shall not seek or agree to any
order of any court or other governmental authority that would prohibit or otherwise interfere, and shall not take or fail to take any other action if such action or failure would reasonably be expected to have the effect of prohibiting or otherwise
interfering, with the performance of the Company’s indemnification, advancement or other obligations under this Agreement. 

  
 8 

 (b) Severability. If any provision or provisions of this Agreement shall be held to be
invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement
containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by
law; (ii) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (iii) to the fullest extent
possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or
unenforceable) shall be construed so as to give effect to the intent manifested thereby. 
 (c) Notices. All notices, requests,
demands and other communications under this Agreement shall be in writing and shall be deemed duly given (i) on the date of delivery if delivered personally, upon confirmation of receipt, (ii) on the first business day
following the date of dispatch if delivered by a nationally recognized courier service or (iii) on the third business day following the date of mailing if delivered by domestic registered or certified mail, properly addressed, or on the
fifth business day following the date of mailing if sent by airmail from a country outside of North America, to Indemnitee at the address shown on the signature page of this Agreement, to the Company at the address shown on the signature page of
this Agreement, or in either case at such address as subsequently modified by written notice to the other party. 
 (d) Amendment and
Termination. No amendment, modification, termination or cancellation of this Agreement shall be effective unless it is in writing signed by all the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other provisions hereof (whether or not similar), nor shall such waiver constitute a continuing waiver. 
 (e)
Successors and Assigns. This Agreement shall be binding upon the Company and its respective successors and assigns, including without limitation any acquiror of all or substantially all of the Company’s assets or business, any person (as
such term is used in Sections 13(d) and 14(d) of the Exchange Act) that acquires beneficial ownership of securities of the Company representing more than twenty percent (20%) of the total voting power represented by the Company’s then
outstanding Voting Securities (unless waived by the majority of the Board of Directors as of immediately prior to such acquisition of beneficial ownership of securities of the Company) and any survivor of any merger or consolidation to which the
Company is party, and shall inure to the benefit of and be enforceable by Indemnitee and Indemnitee’s estate, spouses, heirs, executors, personal or legal representatives, administrators and assigns. The Company shall require and cause any such
successor, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement as if it were named as the Company herein, and the Company shall not permit any such purchase of assets or
business, acquisition of securities or merger or consolidation to occur 

  
 9 

 
until such written agreement has been executed and delivered. No such assumption and agreement shall relieve the Company of any of its obligations hereunder, and this Agreement shall not
otherwise be assignable by the Company. This Agreement is personal in nature and neither of the parties hereto shall, without the consent of the other, assign or delegate this Agreement or any rights or obligations. Without limiting the generality
or effect of the foregoing, Indemnitee’s right to receive payments hereunder shall not be assignable, whether by pledge, creation of a security interest or otherwise, other than by a transfer by Indemnitee’s will or by estate law, and, in
the event of any attempted assignment or transfer contrary to this Section 8(e), the Company shall have no liability to pay any amount so attempted to be assigned or transferred. 

(f) Choice of Law; Consent to Jurisdiction. This Agreement shall be governed by and its provisions construed in accordance with the
laws of the State of Nevada, as applied to contracts between Nevada residents entered into and to be performed entirely within Nevada, without regard to the conflict of law principles thereof. To the fullest extent permitted by law, and unless the
Company consents in writing to the selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada, shall be the sole and exclusive forum for all purposes in connection with any Proceeding which arises out of or relates
to this Agreement. 
 (g) Integration and Entire Agreement. This Agreement sets forth the entire understanding between the parties
hereto and supersedes and merges all previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter hereof between the parties hereto, provided that the provisions hereof shall not supersede the
provisions of the Company’s or any such subsidiary’s articles or certificate of incorporation, bylaws or other organizational agreement or instrument of the Company, any other agreement to which Indemnitee and the Company or any of its
subsidiaries are party, any vote of the stockholders or resolution of the directors of the Company or any of its subsidiaries, the NRS, any other applicable law or any liability insurance policy, to the extent any such provisions shall be more
favorable to Indemnitee than the provisions hereof. 
 (h) Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall constitute an original, and all of which together shall constitute one and the same agreement. 
 [Remainder of this
page intentionally left blank] 

  
 10 

 IN WITNESS WHEREOF, the parties hereto have executed
and delivered this Indemnification Agreement as of the date first above written. 
  

			
	PIERIS PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

 
			
		
	Address:	 	  

		 	  

		 	  

  

			
	AGREED TO AND ACCEPTED:
	
	INDEMNITEE
		
	By:	 	  

	Name:	 	
	Title:	 	

			
		
	Address:	 	  

		 	  

		 	  

 [Signature Page to Indemnification Agreement]EX-10.11

 EXHIBIT 10.11 

Management Agreement (the “Agreement”) 

between 
  

	1.	PIERIS AG, Lise-Meitner-Straße 30, 85354 Freising-Weihenstephan, represented by the Supervisory Board 

  

					
		 	- hereinafter referred to as the “Company”-
			
		 	and	 	

  

	2.	Stephen S. Yoder, Herterichstrasse 65a, 81479 München 

  

					
		 	- hereinafter referred to as the “CEO” -

 - Company and CEO herein collectively also referred to as the “Parties” - 

§ 1 
 Start and Term
of the employment 
  

	1.	The employment shall commence on January 1, 2010, and is entered into for a period of 18 (eighteen) months (the “Term”), i.e. this Agreement will end on June 30, 2011. This Agreement will be
extended automatically for 1 (one) year, unless it has been terminated in writing 6 (six) months prior to the end of the Term. 

  

	2.	The right to effect termination without period of notice for due cause (aus wichtigem Grund) shall remain unaffected. 

 

	3.	Any termination must be in writing. 

 § 2 

Activity 
  

	1.	The CEO shall be employed as a Chief Executive Officer (Vorstandsvorsitzender). The field of work shall cover especially general management and business / corporate development. The CEO shall conduct the
affairs of the Company with the due care and diligence of a prudent and conscientious business manager pursuant to the provisions of law, the Articles of Association, the Rules of Procedure for the Board of Managing Directors as issued by the
Supervisory Board, and this Agreement. He shall safeguard the Company’s interests and shall devote his full working capacity exclusively to the Company. 

  

	2.	In connection with this Agreement and, unless explicitly agreed otherwise in writing, without any additional remuneration, the CEO shall, upon request of the Company, also assume or resign functions in other
enterprises which are affiliated with the Company (sec. 15 German Stock Companies Act (AktG)). This shall apply accordingly with respect to honorary functions in associations and professional organizations, in which the Company or an affiliated
company is a member. 

	3.	The Company is entitled to release the CEO at any time from his work with the continued payment of his gross basic remuneration according to § 4 (1) and while offsetting his residual entitlement to
vacation. 

  

	4.	The place of work is Freising. 

 § 3 

Working hours 
  

	1.	The CEO shall dedicate his entire working capacity to the Company, at least 40 hours a week. The duration and the starting and finishing times of the daily working hours shall be determined by the CEO himself
according to his set task within the respectively valid local working hours regulations, in which respect he must take account of operational interests and the respectively valid Company regulations. 

 

	2.	The CEO is obliged to do overtime or additional work. Overtime is to be done as is required by the situation-related scope of work and in so far as this is legally permissible. The additional work is compensated
by the regular salary according to § 4 (1). 

 § 4 

Salary, other benefits 
  

	1.	The CEO shall receive for his contractual employment an annual gross salary of EUR 210,000.00 (in words: Euro two-hundred thousand and ten), payable in twelve (12) equal monthly instalments through transfer
to the account to be designated by the CEO with a bank located within Germany. The aforementioned instalments will be paid the last day of each month. 

  

	2.	In addition to the remuneration provided for under § 4 (1), however, dependent upon the achievement of certain targets to be agreed on between the Parties, the CEO shall receive an annual bonus payment of EUR
50,000.00 (in words: Euro fifty-thousand) gross (the “Bonus”). The Bonus will be paid each year at year’s end, i.e. December 31, and will be paid pro rata temporis if the employment has not existed the entire year
depending on the achievement of the agreed targets, whereby the determination of the fulfilment of the agreed targets is within the sole discretion of the Company. 

 

	3.	The CEO shall be eligible to participate in the option pool in such way that the CEO shall be granted a stake of 2,5% in the Company (the “Exit Fee”) in the event of a sale of the shares in the
Company or a sale of the assets of the Company (the “Exit”). 

  

	4.	In the event of an Exit resulting in a purchase price exceeding EUR 150 Mio., the CEO shall be entitled to a success fee (the “Success Fee”). The Success Fee shall be calculated as follows:

  

			
		
	Purchase Price > EUR 150 Mio. £EUR 200 Mio.	  	
		
	0,25% of all net proceeds (i.e. after deduction of all transaction costs).	  	

  
 - 2 / 8 - 

			
		
	Purchase Price > EUR 200 Mio. £EUR 250 Mio.	  	
		
	0,5% of all net proceeds (i.e. after deduction of all transaction costs).	  	
		
	Purchase Price > EUR 250 Mio. £ EUR 300 Mio.	  	
		
	0,75% of all net proceeds (i.e. after deduction of all transaction costs).	  	
		
	Purchase Price > EUR 300 Mio.	  	
		
	1,0% of all net proceeds (i.e. after deduction of all transaction costs).	  	

  

	5.	In the event that (i) the Company terminates the Agreement pursuant to § 1 (1) and (ii) the net proceeds (i.e. after deduction of all transaction costs) exceed an amount of EUR 150 Mio., the
Exit Fee and the Success Fee shall be reduced by 33% if the Exit is carried out within six (6) months after termination notice and by 67% if the Exit is carried out within twelve (12) months after termination notice. For the avoidance of
doubt, in the event that (i) the Company terminates the Agreement without period of notice for due shall not be entitled to an Exit Fee and he shall not be entitled to a Success Fee. 

 

	6.	In case of an additional dilutive financing round by the Company, the Exit Fee and the Success Fee may be adjusted by the supervisory board, accordingly, in good faith. 

 

	7.	The Company will lease a car for the CEO. The Company shall bear all acquisition costs / costs of leasing and all running costs such as gasoline, repairs, insurances etc. (the “Care Allowance”).
The Car Allowance shall be limited to a maximum of EUR 1,100 plus VAT per month. The CEO is entitled to use the car for private purposes. As far as this private use is taxable, any such taxes shall be borne by the CEO. The CEO shall return the car
and any other equipment together with the relevant documentation, in particular the registration papers, to the Company at the end of the Term. The same shall apply if the Company releases the CEO from his work according to § 2 (4).

  

	8.	The Company shall also reimburse the relocation costs incurred to the CEO due to the relocation from his current domicile to a domicile near Freising upon submission of the respective receipts. The reimbursement
of the relocations costs shall be limited to a maximum of EUR 10,000 (in words: Euro ten thousand). 

  

	9.	The CEO undertakes to repay any overpayments of salary, including claims arising from the incorrect calculation of taxes and voluntary benefits, to the Company without delay. The CEO waives in this respect the
assertion of a plea of a loss of enrichment according to § 818 (3) of the German Civil Code (Bürgerliches Gesetzbuch). 

  
 - 3 / 8 - 

 § 5 

Travel Expenses 
 The CEO
shall receive the reimbursement of his expenses at the fiscally recognized rates for trips, which are necessary in the Company’s interest. All further details are regulated by the respective valid Company guidelines. 

§ 6 
 Temporary
incapacity to work, 
 continued payment of salary in the event of illness 

 

	1.	The CEO shall notify the Company without delay of every instance of the temporary incapacity to work and its probable duration. On request, the reasons for the temporary inability to work must be indicated.

  

	2.	If the CEO is unable to work on account of the temporary incapacity to work due to illness for which he is not responsible, then the Company shall continue to pay his remuneration for a period of 3 (three)
months, but no longer than the duration of this Agreement. Reimbursements made by third parties to this effect will be deducted. 

  

	3.	The CEO shall assign his entitlement to compensation to the Company if he sustains injury at the hands of a third party and the Company continues to pay his salary in the case of illness. He is obliged to provide
the Company without delay with all the information necessary to pursue said claims. The CEO shall remain obliged to pursue all claims against third parties. 

§ 7 
 Leave 

 

	1.	The CEO shall receive 27 working days’ leave every calendar year. The CEO will take the Company’s respective interests into account. 

 

	2.	As far as the CEO cannot take the leave until the end of the year due to reasons he is not responsible for, he may take the leave until June 30 of the following year; if the leave is not taken until that point in
time, the claim for vacation shall forfeit without any replacement. 

  

	3.	Leave shall only be granted leave pro rata temporis in the year of the commencement and the termination of this Agreement. 

§ 8 
 Secondary
employment 
 and Non-compete obligation 
  

	1.	The CEO shall devote his entire working capacity and all of his knowledge, experience, and know-how to the service of the Company and the enterprises affiliated with it. The CEO is free to set his own working
hours, which shall be subject to his responsibilities and the requirements of the business. 

  
 - 4 / 8 - 

	2.	Any other gainful employment requires prior written approval by the Supervisory Board. The assumption of offices in supervisory bodies of other enterprises or of honorary positions in organizations requires prior
written approval by the Company. Sec. 88 of the German Stock Corporation Act shall remain unaffected. 

  

	3.	The Company may deny or, at any time, revoke its approval of a reported secondary activity only if the respective secondary activity, on its own or in conjunction with other secondary activities, raises the prospect of
an impairment of the CEO’s activity for the Company or for enterprises affiliated with it in the future, or of other interests of the Company or of enterprises affiliated with it in the future. 

 

	4.	The CEO shall on request of the Company, at any time, but at the latest on termination of this Agreement, resign any offices in supervisory bodies of other enterprises or honorary positions in organizations he assumed
in the interest of the Company. 

  

	5.	The CEO shall not be permitted, during the Term, to set up, purchase or participate directly or indirectly in any company, which is in competition with the Company. The purchase of shares of stock and / or business
interests, which causes neither any majority shareholding nor any blocking minority within such an enterprise, shall not be barred according to the above mentioned restraint. This Non-Compete Covenant shall only apply to the business areas of
activity the Manager was engaged in while performing his contractual duties during the past two years before the end of this Management Agreement. At present, this relates to the areas of activity concerning the discovery and development of
Anticalins. This Non-Compete Covenant shall only apply to the geographical region the CEO was engaged in while performing his contractual duties during the past two years before the end of this Service Contract. 

§ 9 
 Professional
development 
 The costs for professional development measures, which are in the Company’s interest, shall be borne by the Company.

 § 10 

Notification of alterations to personal details 

The CEO must notify the Company without delay of alterations to his personal status and alterations to other data which is contained in the
personnel questionnaire. 
 § 11 

Duty of care; return obligation 
  

	1.	The CEO shall be obliged to hold the articles put at his disposal (e.g. keys, electronic data, etc.) in safekeeping. 

  

	2.	 At the Company’s request and at the latest when he leaves Company’s service, the CEO shall return to the Company without delay and without
being requested to do so all files and other documents which concern the business operations of the Company or its 

  
 - 5 / 8 - 

	 	
affiliated companies which are in his possession or subject to his access - especially all plans, customer lists, price lists, printed matter, certificates, drawings, notes, drafts - and also
copies of the said articles, regardless of whether he received them from the Company or from its affiliated companies. 

§ 12 

Confidentiality obligation 
  

	1.	The CEO undertakes to maintain secrecy on all business and company secrets, which he learns during his employment, and also on all other business and company facts of the employment. This shall not apply to facts, which
are public knowledge. 

  

	2.	The confidentiality obligation shall also apply to the time after the termination of the employment. 

  

	3.	During the period of the employment and any time thereafter, the CEO is also obliged to maintain secrecy on the contents of this contract. 

 

	4.	A breach of this unconditional obligation shall constitute a serious infringement of the CEO’s contractual employment obligations, which if repeated entitles the Company to terminate the employment without notice
period. 

 § 13 

IP Protection 
  

	1.	The CEO shall disclose and assign to the Company promptly and fully any future work (including computer software programs) and any invention, improvement, discovery, process, formula, technique, method, trade secret, or
other intellectual property, whether or not patentable, whether or not copyrightable, that is made, conceived, developed, or first reduced to practice, either alone or jointly with others, including any associated trade marks, trade names and good
will in the area of the Company’s business field as described in § 2 of the Articles of Association of the Company and all rights to any related know-how (hereinafter referred to as “Inventions”). 

 

	2.	The CEO hereby assigns to the Company all of his or his right, title and interest in and with respect to any future Inventions, including in particular the right to copy, disseminate, transfer to third parties, (sub-)
license exclusively or non-exclusively, adapt and/or modify any such Invention and to apply for intellectual property rights in the Company’s own name. To the extent the assignment should not be legally valid, the CEO hereby grants to the
Company an exclusive license to use such Invention as described for the entire life of such right. The CEO hereby waives any moral rights he may have under copyright laws, including in particular the right to publish any work, the right to be named
as author and the right of access to any work, to the extent legally permitted. 

  

	3.	Such assignment or license shall be deemed compensated by the regular salary according to § 4 (1) above. The parties assume, and hereby agree, that the salary is an appropriate compensation for such assignment or
license. 

  
 - 6 / 8 - 

 § 14 

Ancillary agreements and contractual amendments 

Verbal ancillary agreements to this contract have not been made. Amendments and supplements to this contract must be made in writing in order
to be effective. The same shall apply to this requirement of the written form. 
 § 15 

Expiry deadlines 
  

	1.	The claims of both parties arising from the employment and such claims in connection with the employment shall lapse if they have not been asserted in writing against the other contracting party within three months
after falling due. 

  

	2.	If the counter-party rejects the claim or does not reply within two weeks after the assertion of the claim, then the said claim shall lapse if it is not asserted in court within a period of 3 further months after the
rejection or the expiry of the deadline. This shall not apply to claims for payment of the CEO which fall due during dismissal proceedings and which depend on the outcome of the proceedings. For these claims, the expiry deadline of three months
shall commence after the final and absolute conclusion of the unlawful dismissal proceedings. 

 § 16 

Miscellaneous 
  

	1.	If a provision of this contract is or becomes legally ineffective or unfeasible in whole or in part, then the validity of the remaining provisions of this contract shall not thus be affected in case of doubt. On the
contrary, the provision, which is legally ineffective or unfeasible in whole or in part, is to be replaced by a provision, which is closest in commercial terms to the meaning and purpose of the provision, which is ineffective or unfeasible in whole
or in part. The same shall apply in the case of gaps in this contract. 

  

	2.	If, as a result of an alteration to the legislation or Supreme Court rulings or on account of other circumstances, a provision of this contract becomes invalid, then the provision shall automatically be adapted in line
with the new legal position. The validity of the remaining provisions shall not thus be affected. 

  

	3.	Any amendment to this Agreement shall only be effective when entered into in writing and signed on behalf of both Parties. 

  

	4.	This Agreement shall be governed exclusively by German law. 

  
 - 7 / 8 - 

 § 17 

Copy of contract 
 The CEO
confirms by his own signature that he has received a written copy of this contract. 
  

					
	Freising, Aug. 30 2009	 		  	30. Aug 2009
			
	 /s/ Hans Küpper
	 		  	 /s/ Stephen S. Yoder

	Company	 		  	CEO

  
 - 8 / 8 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]